Bionano Announces Peer-Reviewed Publication From Its Clinical Study Designed To Support OGM As Part Of Standard Of Care In Genetic Disease Testing
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics, Inc. (NASDAQ:BNGO) announced a peer-reviewed publication from a clinical study supporting optical genome mapping (OGM) as part of standard care in genetic disease testing. The study showed a 99.5% concordance rate for pathogenic variants against standard methods and an increased detection rate of 6% to 50% for pathogenic variants with OGM. The study suggests OGM could streamline workflows, reduce costs, and be considered a first-tier method for postnatal genetic disorders.
January 11, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano Genomics' peer-reviewed publication demonstrates the effectiveness of its OGM technology in genetic disease testing, with high concordance rates and potential to improve detection rates of pathogenic variants.
The positive results from the clinical study are likely to increase investor confidence in Bionano's OGM technology. The high concordance rate and potential to streamline lab workflows could lead to increased adoption of OGM, potentially boosting Bionano's market share and revenues in the genetic testing market. The news is directly related to Bionano's core product and represents a significant development in its validation, which is why the score is positive, relevance is high, and importance is significant.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100